Dyslipidemia and Angiotensin II and Atherogenesis

Gill, Muhammad T.; Chen, Jaiwei; Mehta, Jawahar L.

doi:10.1007/0-387-27826-5_12

Basic Science for the Cardiologist

2006

DOI: 10.1007/0-387-27826-5_12

|View full text |Cite

Dyslipidemia and Angiotensin II and Atherogenesis

Muhammad T. Gill

Jaiwei Chen

Jawahar L. Mehta

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2008

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These actions involve the low-density lipoprotein receptors of the ventricles and arterioles and account for their important role in treating hyperlipidemia and atherosclerosis, as well as mediating other events. 6 In this regard, a series of studies was begun in Mehta's laboratory that demonstrated that angiotensin II initiated yet another mechanism for producing oxidative stress. Thus, with angiotensin II type 1 receptor stimulation there is expression of a LOX-1.…”

mentioning

confidence: 99%

Excitement of Clinical Investigation

Fröhlich

2008

Hypertension

View full text Add to dashboard Cite

E normous personal satisfaction is frequently derived from experiences resulting from systematic clinical investigation. Such are the lessons that have been learned from the tremendous insight that has evolved concerning the careful clinical and fundamental study of new therapeutic agents, events after their release for general clinical use. This has been the case derived from exciting gains into the cardiac and vascular remodeling after introduction of the angiotensinconverting enzyme inhibitors and the statins.According to the editors, an editorial commentary is intended to "highlight, provide a further perspective, and enhance the overall significance of a study that is novel, timely, and contributes to our understanding of the physiology, pathophysiology, clinical treatment or prevention of hypertension." To my way of thinking, there is no better example of such an article to fulfill these criteria than "Modulation of Angiotensin II-Mediated Hypertension and Cardiac Remodeling by Lectin-Like, Oxidized Low-Density Lipoprotein Receptor-1 Deletion" by Hu et al. 1 Inherent in this commentary are its key words: angiotensin II, cardiac remodeling, and lectinlike, oxidized low-density lipoprotein receptor-1 (LOX-1) deletion. Moreover, central to its thesis are the concept and mechanisms of cardiovascular "remodeling."The role of angiotensin in cardiac remodeling was first introduced into pathophysiology, clinical treatment, and prevention by Marc A. and Janice M. Pfeffer in 1988 after a discussion (which I witnessed) with Eugene Braunwald. That conversation concerned submission of an abstract on the benefits of prolonged survival with long-term captopril therapy of rats with myocardial infarction and heart failure for consideration at the forthcoming annual scientific meeting of the American Heart Association. 2 At that time, Braunwald suggested the need for a "hook" so that the article could be accepted on the "main arena" of the program rather than at a smaller session. He thereupon suggested the term "remodeling." That abstract was accepted on that year's "arena session," and I suggest that we have all been hooked on that term ever since. Their laboratory findings were subsequently confirmed clinically in a mechanistic trial of cardiac enlargement after myocardial infarction. 3 The translation of the concept and fundamental work demonstrating inhibition of ventricular remodeling to improve prognosis was then demonstrated in the multicenter clinical Survival and Ventricular Enlargement Trial 4 ; and it was subsequently confirmed by a number of trials bearing a host of acronyms. 5 Each of these trials demonstrated the following: inhibition of the renin-angiotensin system prevented remodeling of the left ventricle, subsequent development of left ventricular failure, a second myocardial infarction, high-grade arrhythmias, and death. I am personally thrilled by this anecdotal story, because the initial experimental investigations were the substance of the late Janice Pfeffer's graduate thesis conducted in my laborato...

show abstract

mentioning

confidence: 99%

Excitement of Clinical Investigation

Fröhlich

2008

Hypertension

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Dyslipidemia and Angiotensin II and Atherogenesis

Cited by 1 publication

References 61 publications

Excitement of Clinical Investigation

Excitement of Clinical Investigation

Contact Info

Product

Resources

About